Silence Therapeutics plc (SLNCF) Q1 2024 Earnings Report

Silence Therapeutics reported QQ1 2024 revenue of £12.406 million, up 9.07% year over year (YoY) and 491.04% quarter over quarter (QoQ). The remarkable QoQ surge likely reflects the timing of collaboration-related revenue recognition, though the company also posted solid gross margins of 82.16%. The operating loss widened as the company continues to invest aggressively in R&D, delivering an EBITDA of approximately £-4.036 million and net income of £-1.878 million. Earnings per share stood at £-0.0426 (diluted). R&D spend remained the dominant expense line (approx. £9.179 million), with SG&A at £5.17 million, culminating in total operating expenses of £16.562 million (costs and expenses). Despite the negative quarterly bottom line, Silence entered QQ1 with a robust liquidity profile: cash and cash equivalents of £113.1 million and total cash equivalents plus short-term investments of roughly £152.8 million, alongside a net cash position (net debt) of approximately £-112.8 million driven by substantive financing activity. The balance sheet shows a high current ratio (~10.15x), a meaningful level of non-current collaboration-related deferred revenue (£56.208 million), and modest leverage, positioning the company to advance its early-stage RNAi pipeline (SLN360 and SLN124) under existing and potential partner funding. Near-term catalysts hinge on clinical readouts and partnership developments, with management commentary not published in the provided transcript data.